Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

NRF commits R30-million for research at the UFS
2007-02-20

The National Research Foundation (NRF) has committed approximately R30-million for various research projects at the University of the Free State (UFS).
 
According to Prof Frans Swanepoel, Director of Research Development at the UFS, the NRF has also approved all eight research niche areas that were submitted to the NRF, the highest number approved at any university in the country.
 
Prof Swanepoel said the 24 research projects for which funding had been obtained from the NRF ranged from traditional healing and HIV/Aids/tuberculosis management, practices of the paediatric anti-retroviral programme at the UFS to nano-materials synthesis and characterisation.
 
He said the eight research niche areas were part of an initiative at the UFS to establish strategic clusters of academic and research excellence.
 
“There will be six strategic academic clusters at the UFS and the eight NRF-approved research niche areas will form part of them,” Prof Swanepoel said.
 
The six strategic clusters are:
1.         Water management in water-scarce areas
2.         New frontiers in poverty reduction and sustainable development
3.         Social transformation in diverse societies
4.         Ecologically sound value chains for agricultural commodities
5.         Materials and nano sciences
6.         Advanced bio-molecular research
 
Prof Swanepoel said that the UFS had also submitted five proposals in terms of an NRF initiative to establish research chairs at South African universities.
 
“Linked to our intention to establish six strategic academic clusters, five proposals for the South African Research Chair Initiative (SARCHi) were submitted. All five pre-proposals were accepted in the first round of screening, and successful candidates have been invited to submit full proposals by the end of February,” he said.
 
The proposed research chairs are:
 
Petro- and organometallic chemistry
Biocatalytic and biomimetic oxidation-reduction systems
Nano-solid state lighting
People’s health and well-being
Water management
 
Speaking at the official opening of the university earlier this month, the Rector and Vice-Chancellor of the UFS, Prof Frederick Fourie, said: “The cluster initiative represents a strategic initiative to focus our energies in a few key areas, investing in them so that the UFS can become an international leader in those fields.”
 
“A medium sized university such as the UFS with relatively limited human, physical and financial resources has to achieve this kind of ‘critical mass’ and synergy to establish itself in terms of its core functions of teaching/learning, research and community engagement,” said Prof Fourie.
 
Media release
Issued by: Lacea Loader
Media Representative
Tel: 051 401 2584
Cell: 083 645 2454
20 February 2007

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept